<DOC>
	<DOCNO>NCT00562003</DOCNO>
	<brief_summary>The primary purpose study determine maximally tolerate dose spectrum toxicity encounter intraperitoneal delivery RGD modify conditionally replicative adenovirus ( Ad5-Delta 24RGD ) patient recurrent ovarian cancer . Secondary objective : - To determine biologic effect encounter intraperitoneal delivery Ad5-Delta 24RGD patient recurrent ovarian cancer cell - To determine immunologic response generate Ad5-Delta 24RGD administer intraperitoneally patient recurrent ovarian adenocarcinoma - To determine potential clinical activity Ad5-Delta 24RGD administer intraperitoneally patient recurrent ovarian adenocarcinoma</brief_summary>
	<brief_title>Safety Study Genetically Modified Adenovirus Ovarian Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Patients must histologically document invasive epithelial ovarian extraovarian adenocarcinoma Patients must persistent recurrent disease standard debulking/staging surgery conventional chemotherapy.Prior chemotherapy must include taxane/platinum base regimen Patients must evidence intraabdominal disease ; disease may measurable nonmeasurable Patients must GOG performance status 0 , 1 , 2 , life expectancy great 3 month Patients must adequate hematologic , renal , cardiac , pulmonary , coagulation , hepatic function define : 1 . WBC &gt; 3,000 ul 2 . Granulocytes &gt; 1,500 ul 3 . Platelets &gt; 100,000 4 . Creatinine clearance ( actual calculate ) &gt; 80 mg/dl serum creatinine &lt; 2.0 5 . Serum transaminases &lt; 2.5x upper limit normal 6 . Normal serum bilirubin 7 . PT/PTT/INR &lt; 1.5 x institutional ULN 8 . Ejection fraction echocardiogram &gt; 55 % 9 . O2 saturation &gt; 92 % Patients must 19 year old ( mandate Alabama state law ) must sign informed consent Patients epithelial ovarian tumor low malignant potential ( without invasive implant ) , ovarian stromal tumor , germ cell tumor ovary ineligible participate study Patients site disease locate beyond abdominal cavity ineligible participate study Patients pregnant lactate ineligible participate study Patients GOG performance status 3 4 ineligible participate study Patients active heart disease ( characterized angina , unstable arrhythmia , congestive heart failure EF &lt; 55 % , pulmonary hypertension ) , active chronic debilitate pulmonary disease ( i.e. , active pneumonia , severe COPD , pulmonary edema , O2 saturation &lt; 92 % ) , coagulation disorder ( i.e. , bleed disorder , therapeutic anticoagulant )</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Ovarian cancer study</keyword>
</DOC>